



Altimune to Participate in Upcoming Investor Conferences

October 10, 2019

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:

H.C. Wainwright 3rd Annual NASH Investor Conference

Date: Monday, October 21
Time: 11:20am ET
Speaker: M. Scott Harris M.D., Chief Medical Officer
Location: St. Regis Hotel, New York City
Webcast: <https://ir.altimmune.com/investors/events-and-presentations>

BIO Investor Forum

Date: Wednesday, October 23
Time: 12:45pm ET/9:45am PT
Speaker: Vipin K. Garg Ph. D., President and Chief Executive Officer
Location: Westin St. Francis Hotel, San Francisco, CA
Webcast: <https://ir.altimmune.com/investors/events-and-presentations>

Jefferies 2019 London Healthcare Conference

Date: November 20 and November 21 (*one-on-one meetings only*)
Attendees: Vipin K. Garg Ph.D., President and Chief Executive Officer
Will Brown, Chief Financial Officer
Location: Waldorf Hilton, London, UK

About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company's diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShield™ and NasoVAX™). For more information on Altimune, please visit www.altimmune.com.

Contacts

Will Brown
Chief Financial Officer
Phone: 240-654-1450
Email: wbrown@altimmune.com

Ashley R. Robinson
Managing Director LifeSci Advisors
Phone: 617-535-7742
Email: arr@lifesciadvisors.com



Source: Altimune, Inc.